

# The Role of Artificial Intelligence in Identifying Depression and Anxiety: A Comprehensive Literature Review

Review began 03/08/2024  
Review ended 03/15/2024  
Published 03/19/2024

© Copyright 2024

Zafar et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Fabeha Zafar <sup>1</sup>, Laraib Fakhare Alam <sup>2</sup>, Rafael R. Vivas <sup>3</sup>, Jada Wang <sup>4</sup>, See Jia Whei <sup>5</sup>, Sameer Mehmood <sup>6</sup>, Amirali Sadeghzadegan <sup>7</sup>, Mohit Lakkimsetti <sup>8</sup>, Zahra Nazir <sup>9</sup>

1. Internal Medicine, Dow University of Health Sciences (DUHS), Karachi, PAK 2. Internal Medicine, Ministry of Health, Kuwait, KWT 3. Nutrition, Food and Exercise Sciences, Florida State University College of Human Sciences, Tallahassee, USA 4. Medicine, St. George's University, Brooklyn, USA 5. Internal Medicine, Sriwijaya University, Palembang, IDN 6. Medicine, Jinnah Sindh Medical University, Karachi, PAK 7. General Medicine, Marmara University School of Medicine, Istanbul, TUR 8. Internal Medicine, Mamata Medical College, Khammam, IND 9. Internal Medicine, Combined Military Hospital, Quetta, Quetta, PAK

Corresponding author: Zahra Nazir, naz\_zahra93@outlook.com

---

## Abstract

This narrative literature review undertakes a comprehensive examination of the burgeoning field, tracing the development of artificial intelligence (AI)-powered tools for depression and anxiety detection from the level of intricate algorithms to practical applications. Delivering essential mental health care services is now a significant public health priority. In recent years, AI has become a game-changer in the early identification and intervention of these pervasive mental health disorders. AI tools can potentially empower behavioral healthcare services by helping psychiatrists collect objective data on patients' progress and tasks. This study emphasizes the current understanding of AI, the different types of AI, its current use in multiple mental health disorders, advantages, disadvantages, and future potentials. As technology develops and the digitalization of the modern era increases, there will be a rise in the application of artificial intelligence in psychiatry; therefore, a comprehensive understanding will be needed. We searched PubMed, Google Scholar, and Science Direct using keywords for this. In a recent review of studies using electronic health records (EHR) with AI and machine learning techniques for diagnosing all clinical conditions, roughly 99 publications have been found. Out of these, 35 studies were identified for mental health disorders in all age groups, and among them, six studies utilized EHR data sources. By critically analyzing prominent scholarly works, we aim to illuminate the current state of this technology, exploring its successes, limitations, and future directions. In doing so, we hope to contribute to a nuanced understanding of AI's potential to revolutionize mental health diagnostics and pave the way for further research and development in this critically important domain.

---

**Categories:** Family/General Practice, Psychology, Environmental Health

**Keywords:** ai chatbot, machine learning (ml), generalized anxiety disorder (gad), depression, artificial intelligence in medicine

## Introduction And Background

Every person tends to react emotionally in a particular way, usually independent of the external stimulus. The reaction revolves around three components of emotions: subjective feelings of the individual, physiological changes, and a person's behavior to express emotions [1]. Regulation of emotions occurs through three main parts of the brain. The brainstem is responsible for an unconscious drive. The limbic system modifies the emotional response based on the environment, and the pre-frontal cortex deals with conscious emotions and feelings and controls them [2,3]. These brain areas are subject to external factors, which can cause deregulation in their functioning, eventually leading to abnormal behavioral traits. These combined changes consequently lead to a variety of mood disorders, including anxiety, depressive disorders, psychosis, and other personality disorders [4].

The insidious dark shadows of depression and anxiety afflict millions globally, exacting a heavy toll on individual well-being and societal productivity [5]. According to the WHO Facts Sheets 2023, 5% and 4% of the global population are affected, respectively [5,6]. Moreover, the evidence suggests that over the last decade, the incidence of depression has increased worldwide [7]. The relationship between depression and anxiety has been controversial for an extended period. Based on recent evidence, neurobiological and genetic similarities have been seen between the two. Approximately 85% of patients with depression are shown to exhibit significant symptoms of anxiety. Similarly, in about 90% of patients with anxiety disorders, comorbid depression is seen [8,9].

Artificial intelligence (AI) has recently emerged as a potential game-changer in the early identification and intervention of these pervasive mental health disorders [10-16]. While the application of this technology is growing, some of the more concrete applications of AI in mental health for identifying and managing

### How to cite this article

Zafar F, Fakhare Alam L, Vivas R R, et al. (March 19, 2024) The Role of Artificial Intelligence in Identifying Depression and Anxiety: A Comprehensive Literature Review. Cureus 16(3): e56472. DOI 10.7759/cureus.56472

depression and anxiety include early detection and risk assessment, improved diagnosis and assessment, personalized treatment and intervention, and research and development [10-20].

Various tests can be performed using former techniques and machine learning (ML) algorithms to detect emotional imbalances under different scenarios. Interestingly, this has led to the development of emotionally intelligent machines based on various AI-based approaches to detect emotions in human beings, depression being one of them.

Text-based emotion recognition uses machine learning algorithms like Naive-Bayes and support vector machines (SVM). Principal component analysis (PCA) is a machine-learning technique that detects emotions through facial expressions, speech, and gestures. An emotion-detecting system is used in video gaming and customer reviews to detect fear/excitement in the player and the customer's emotions, respectively [21]. Certain companies also use emotional analytics during the recruitment process for candidate selection. Haar-cascade algorithms, K-nearest neighbors (KNN) classification technique, and optical character reader (OCR) are a few techniques that use AI and artificial neural networks to detect depression through facial expression. Partial least square algorithm detects emotion through vocal stimuli. ML techniques, for example, term frequency-inverse document frequency (TF-IDF), long term short term (LTST) - radial neural networks (RNN), logistic regression, and linear support vector, are used to detect depression through tweets. Sentiment analysis with the use of the natural language processing (NLP) technique is used in emotion recognition in tweets [21].

## **Other applications of AI in screening, diagnosis, and treatment**

### *Chatbots and Virtual Assistants*

Chatbots and virtual assistants can conduct initial patient screenings and assess symptom severity through personalized conversational interactions [17].

### *Wearable and Mobile Sensors*

Monitoring sleep patterns, activity levels, heart rate, and voice intonation through wearable devices can provide objective data for identifying early symptoms [11,13,19].

### *Neuroimaging Analysis*

AI can analyze brain scans to identify potential biomarkers for depression and anxiety.

### *Tailored Therapy Recommendations*

AI algorithms can analyze a patient's data and suggest personalized treatment plans.

### *Remote Diagnosis, Monitoring, and Support*

AI-powered chatbots and interactive virtual agents can assist depression detection and provide ongoing support and monitoring, improving treatment adherence and engagement [21].

### *Digital Therapeutic Interventions*

AI-powered apps and programs can provide cognitive behavioral therapy (CBT), mindfulness exercises, and other evidence-based interventions for self-management of depression and anxiety; for instance, Youper is a mobile app used in the treatment of depression and anxiety [22].

### *Predicting Treatment Outcomes*

AI can help interpret patients that might respond to specific interventions, furthering personalized medical approaches.

In addition to AI's benefits to mental health, its application has a few challenges. These include a lack of accountability and a lack of standard ethical and legal framework [23]. This narrative literature review undertakes a comprehensive examination of the burgeoning field, tracing the development of AI-powered tools for depression, anxiety diagnosis, and treatment from the level of intricate algorithms to practical applications. By critically analyzing prominent scholarly works, we aim to illuminate the current state of this technology, exploring its successes, limitations, and future directions. In doing so, we hope to contribute to a nuanced understanding of AI's potential to revolutionize mental health diagnostics and pave the way for further research and development in this critically important domain.

## Review

Artificial intelligence has emerged as one of the most critical developments in mental health. To properly analyze its application in the screening, diagnosis, and treatment of depression and anxiety, it is essential first to understand the current tools used for this purpose. Accurate diagnosis is crucial when addressing anxiety and depression, this introduction offers an overview of the current diagnostic tools used in clinical practice to identify and assess these disorders, providing insights into medical professionals' methods for diagnosis. Screening individuals for depression can assist in identifying those who require intervention, leading to enhancements in their well-being and overall clinical condition. Concise screening questionnaire tools can be administered with minimal personnel [24]. Conducting screening activities requires training and proficiency, given that identifying depression symptoms can be challenging due to concurrent medical conditions such as pain, cognitive impairment, anxiety, and disability [25].

Major depressive disorder (MDD) is characterized by a range of symptoms that are not dependent on age [26]. To be diagnosed with MDD, an individual must exhibit a persistently sad mood and reduced interest or enjoyment in activities. Additionally, they must experience at least four of the following symptoms for a minimum of two weeks [27]: changes to appetite or body weight, sleep disturbances, restlessness or a sense of slowness, overwhelming fatigue or a persistent lack of energy, difficulty concentrating or making decisions, feelings of unworthiness or inappropriate guilt, contemplation of death or suicidal ideation.

In depression screening, two widely utilized tools, the Patient Health Questionnaire-2 (PHQ-2) and the extended Patient Health Questionnaire-9 (PHQ-9), play vital roles in assessing and evaluating depressive symptoms [28]. The scale employs a four-point response system with the following options: 0 (no days), 1 (some days), 2 (more than half of the days), and 3 (almost every day) [29]. To enhance the reliability and validity of depression screening, the PHQ-9 can be used in conjunction with the PHQ-2, providing a comprehensive evaluation [30]. The PHQ-9 extends beyond the PHQ-2 by encompassing all nine symptoms of major depression. An efficient approach involves administering the PHQ-2 and, for those with a positive initial screen, assessing the remaining seven symptoms. Higher PHQ-9 scores indicate greater depression severity, although the score ranges from 0 to 27 [28].

Generalized anxiety disorder (GAD) can be diagnosed using the screening tool form of GAD-7 [24,31]. The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) outlines the diagnostic criteria for GAD. To be diagnosed with GAD, an individual must experience inappropriate anxiety excessive in intensity for at least six months with accompanying symptoms of restlessness or feeling on edge, easily tired, difficulty concentrating, irritability, muscle tension, and sleep disturbances.

The GAD Scale employs a Likert-type rating system featuring four response choices, ranging from 0 (not at all), 1 (several days), 2 (more than half the days), and 3 (almost every day) [32]. This scale assesses anxiety symptoms experienced over the past two weeks, aligning with DSM-IV criteria. The GAD-7 yields scores from 0 to 21 [32]. The GAD-7 provides a foundation for diagnosing patients with GAD, but keep in mind that there are other types of anxiety disorders, such as phobia, social anxiety, panic disorder, and agoraphobia [31]. However, a formal diagnosis can only be made if another underlying medical condition does not explain the symptoms, and healthcare providers must consider the multifactorial causes of health conditions.

Medical diagnostics is the name given to the practice of analyzing patients' symptoms, medical histories, and test results to evaluate potential medical conditions or diseases. As a rule, diagnostic medicine aims to establish what causes an individual health issue to plan the proper treatment. Medical diagnostics often entail diverse diagnostic procedures, including blood test imaging techniques such as X-rays, CT scans, MRI scans, biopsies, and many more.

Following the results of these reports, healthcare providers determine the best course of treatment for their patients. Aside from diagnosing health problems, medical diagnostics can also be employed to track the improvement of a condition, evaluate the effectiveness of a therapy, and identify early signs of problems before they become serious [33]. There is vast scope for AI to transform mental health; it is built on the foundations of individualized patient care and availability [10,34]. AI-powered mental health applications aid in the early identification of mental health disorders, offering personalized treatment and support [10,35,36]. Utilizing these applications does not call for in-person appointments and long waiting periods by offering continuous and seamless support around the clock, thereby providing practical progress in the treatment's effectiveness [10]. AI allows machines and computers to make decisions by learning from data. AI has played a role in revolutionizing mental health support by providing accessible and personalized care to individuals.

### Using Electronic Health Record and novel machine learning approach with AI for diagnosis and treatment of depression and anxiety

Depression and anxiety are highly prevalent mental health disorders, but sadly, many cases are left untreated due to poor identification of risk factors and warning signs. With the recent developments and advancements in research and healthcare, various new methods have evolved to diagnose and treat the above two. With the use of AI, one of the methods in early identification of depression and anxiety is using

primary care Electronic Health Record (EHR) [37].

Administrative healthcare data (AHD) and EHR are used in geriatric mental health research. However, alternative analytic approaches such as ML with AI come into play due to the data's increasing amount and complexity [38]. ML utilizes already established algorithms to perform tasks without specific programmed instructions while continuously learning from the tasks performed.

Analytic strategies employed with EHR and AHD studies involve regression models such as logistic regression, linear regression, or time-to-event models like Cox-proportional hazard models. There is also a growing interest in the potential applications of ML and AI in data analysis of EHR and AHD in mental health studies [10,39]. AI and ML may provide benefits compared to standard biostatic regression analysis, especially when there is high complexity to the underlying data, which has become more familiar with AHD and EHR data as a great range of information is included in these data sources [40].

The application of AI and ML to EHR and AHD analysis is evolving with time, including developing recommendations for using the former two with these datasets and including their studies in biomedical research [41,42]. A recent review of studies using EHR with AI and ML techniques for diagnosis or classification across all clinical conditions has identified about 99 unique publications [43]. Out of these, 28 studies were identified for mental health disorders in all age groups, and among them, six studies utilized EHR data sources [10]. EHR and AHD are rich resources that gather information related to patients' healthcare records and allow us to facilitate this knowledge for research, including mental health. However, obstacles and challenges are associated with using the above two data due to the large sample size, incompleteness, the volume of longitudinal data, and inconsistency [43].

ML and AI can also be used to analyze unstructured data, for example, free-text clinical notes, which are increasingly available in EHR. Incorporation of clinician-generated data from unstructured data sources substantially improves predictive performance as compared to analyses that involve only structured data, for example, laboratory values. This highlights the potential future for research and clinical applications related to EHR and AHD in mental health diseases [44]. ML is used to develop models that assess the probability of individuals developing mental health conditions by analyzing various factors such as genetics, lifestyle, and environmental data [45,46]. Prior research has relied on ML using classification techniques to detect mental health problems [47]. The most commonly used ML techniques in mental health disorder detection include SVM, logistic regression, random forests, decision trees, and artificial neural networks [47]. SVM is a type of supervised learning that falls under standard ML techniques and deals with classifications and regressions [48]. SVM relies on data mining and solves linear and nonlinear classification problems, meaning this technique can handle structured and semi-structured data. Studies done in 2015 [49] and 2017 [50] indicated that SVM has an accuracy of approximately 70%, and another study in 2017 for depression detection showed SVM accuracy of 79% [51].

AI and ML may also affect mental health disease onset, prediction, or progression. Precision medicine, which predicts treatment response and personalizes therapeutic interventions for individuals, is another potential application of the former [52]. Using patients' responses to previous treatments and genetic profiles, ML can recommend personalized therapies and medications deemed more likely effective based on the provided data [53]. Utilizing AI improves treatment outcomes and reduces the trial-and-error approach in mental health care.


## How machine learning and natural language processing contribute to AI in mental health

ML and NLP have an interlocking relationship in artificial intelligence, especially regarding mental health. NLP is a subset of ML that allows machines to understand and generate human language [54]. NLP's linguistic abilities include extracting information from textual data. ML complements NLP's abilities by learning and making informed decisions from data [54]. The collaboration between NLP and ML allows medical professionals to navigate vast data accurately. ML algorithm techniques can help with the early detection of mental health disorders via analyzing data resources such as health records and changes in speech and text patterns [45]. For example, changes in linguistic patterns or the sentiment of texts can be indicative of signs of mental health disorders [46].

NLP enables AI systems to analyze, process, and understand texts and speech similarly to humans [55]. NLP allows AI systems to respond in human language [56]. NLP is adequate at analyzing the emotional tone of texts. For example, chatbots can analyze user inputs to detect signs of distress, anxiety, or depression [57]. From there, chatbots can offer appropriate support or intervention [57]. NLP can be applied directly to individual patient data to predict suicide risk and identify disorders and comorbidities for example Boamente Program uses user's text data via smart phone application to predict suicide ideation [55]. NLP can also be used in health records to automate chart reviews, classify patients, and predict patient-specific outcomes or overall population trends [55]. NLP-powered chatbots are AI-driven systems that engage in individual conversations and can offer human-like, empathetic responses and guidance. The most cost-effective natural language processing is smartphone data, which is easily accessible and contains valuable personal data for analyzing patterns linked to behavioral changes [12,58]. NLP and ML work together in AI-directed mental health care [59]. NLP techniques extract information and enable ML algorithms to analyze data for trends, risk factors, and potential issues [60].

## Categories of artificial intelligence-based diagnostic and therapeutic tools for depression and anxiety

Following are a few examples of application of AI in the diagnosis and treatment of depression and anxiety. It's implication has been mentioned in Figure 1 as well.



**FIGURE 1: Artificial Intelligence and its use in various categories**

Created with BioRender.com

### Chatbot and virtual agents

In the pandemic coronavirus disease 2019 (COVID-19) era, chatbots have been created to assist and enhance mental health care support. AI chatbots have had an increased demand throughout the years. One of their essential usages is their assistance in therapy for mental disorders, with depression being the most common [61]. They play a pivotal role in enhancing the quality of patient responses and can engage with individuals who prefer alternatives to in-person therapy and spare time for medical professionals [62]. AI chatbots have the potential to simulate psychotherapist interactions, assess individual depression levels, and suggest self-help strategies [63]. Additionally, AI chatbots can efficiently handle vast databases of diseases, symptoms, and treatment options [64]. Chatbots assist in diagnosing by asking questions about mood and stress [65-68]. A few examples of chatbots are as follows:

#### *Woebot*

One of the chatbots invented is Woebot, which was specifically made to provide cognitive behavioral therapy (CBT) tools through social media or mobile applications. CBT tool is one of the ways to manage and identify challenging mental health issues. A randomized controlled trial was conducted with 70 subjects, and it was concluded that there was a significant decrease in the Woebot group users [35,66].

#### *Tess*

Tess uses text messaging to coach individuals to overcome their mental distress and to provide therapeutic conversations and ways to cope with their mental health issues [66,68].

#### *Replika*

Replika is a smartphone app that allows users to communicate with an avatar for self-reflection. It allows users to be vulnerable, to open up without constant fear of judgment, and to improve their personality in a better direction [68,69].

*AI-Enabled Companion Bots*

There are also companion bots like Paro and eBear that provide animal therapy to assist with mental health issues such as depression. They teach ways to cope and overcome mental health challenges [65,66,68].

**Wearable devices**

Electronic devices, such as wearable devices with various sensors and technologies, can be worn on the body. The primary goal of these wearables is to provide users with real-time information about their health, activities, or environment. Integrating wearable devices with artificial intelligence has emerged as one of the most significant advancements in AI for screening, diagnosing, and managing depression and anxiety [70-72]. There is a scarcity of mental health practitioners worldwide. Statistics have shown that there are only around nine psychiatrists per 100,000 in high-income countries. In contrast, in low-income countries, the ratio is as low as 0.1 psychiatrists per one million people [73,74]. Hence, developing automated techniques is vital to address this shortage.

Numerous wearable devices are available, including but not limited to smartwatches, smart bands, bright shirts, and smart glasses. The most common device used by most research studies has been an intelligent band [70,75,76]. This can be explained by the fact that they are less distracting and easy to use, which makes them more user-friendly [77]. These wearable devices continuously record users' parameters such as step count (physical activity), heart rate, sleep data, temperature, and blood oxygen. These parameters are significant because studies have shown that depression is associated with a decrease in physical activity, whereas treatment with antidepressants has been shown to increase activity levels significantly [78-80]. Additionally, increased activity is also related to lower depression [81,82].

The association between sleep patterns and depression and anxiety is also well-established [75,83,84]. The relationship of heart rate and heart rate variability with depression and anxiety is also well known [85-87]. Furthermore, it has also been reported that higher body temperature is associated with depression [88,89]. Figure 2 highlights all available wearable devices.




**FIGURE 2: The available wearable devices**

AR: augmented reality, VR: virtual reality

Figure created using flaticon.com

Most studies have shown that wearable AI is often used for diagnosis and screening of anxiety and depression [13,70,75]. These devices can continuously record data and track real-time changes. This data can be integrated with AI, used for screening and diagnosis of depression and anxiety, and utilized for its management. This can help in early diagnosis of depression and anxiety-related symptoms, which in turn can help to prevent depression in individuals [13]. Pre-screening evaluation can also be done via these devices, and individuals can be notified of needing a mental health checkup.

Treatment via the help of wearable devices still needs to be investigated, although some interventions for treatment purposes, including mindfulness and biofeedback therapy, have been studied [76,90]. However, there is still a huge research gap in this field. Hence, further studies and interventions are required to use AI-integrated wearable technology in the treatment of depression and anxiety. Figure 3 highlights how AI is implemented in wearable devices.



**FIGURE 3: Introducing artificial intelligence (AI) in wearable devices**

Source Reference no: [71,73]

### AI in digital gaming interventions and smartphone applications

AI has also played a part in digital gaming interventions [66,68,91]. In the past, digital gaming was used to detect symptoms. Psychoeducation has now evolved into complete programs that improve the psychosocial and cognitive domains of various mental health issues. Many therapeutic services include cognitive behavioral therapy, behavioral modification, social motivation, attention enhancement, and biofeedback. This is appealing to users as games are now easily accessible via smartphones and can improve their user's mental health. Other than that, several smartphone applications have been invented to use AI, such as mindLAMP and BiAffect, which help with mental health conditions such as depression and anxiety to help predict recovery through various data and to assist them in overcoming mental health challenges [68,91].



## Neuroimaging analysis

The increase in artificial intelligence capabilities, especially machine learning algorithms, is a powerful tool for automation neuroimaging data analysis. Complex patterns may be investigated and resolved in the data details of the voluminous databases, looking back at long-standing research that can make human observers also disseminate publications for literature review or neurotic council. This automation saves time and eliminates human error and inter-observer variability, as is often the analysis case. Many studies have shown AI algorithms' ability to analyze neuroimaging data automatically. For instance, machine learning models have been successfully used to identify specific brain regions involved with anxiety and depression, such as the amygdala, anterior cingulate cortex, and prefrontal cortex [92]. AI algorithms hold a significant impact on the detection and effective removal of biomarkers linked to anxiety and depression. Through analyzing detailed information, these algorithms can reveal microstructural, functional, or connectivity differences in the brain that could be potential biomarkers of such diseases. For instance, abnormal connection patterns have been identified as specificity factors in anxiety disorders [93]. Such biomarkers can be detected and quantified by AI algorithms with a high level of accuracy, enabling the refinement of diagnostic criteria. AI can also identify biomarkers and differentiate between various anxiety or depression subtypes. For example, machine-learning approaches have revealed that neuroimaging of major depression and bipolar disorder can differ in species [94]. This implies that AI algorithms can deliver more reliable and personalized diagnoses, which improves treatment planning accuracy.

## Personalized treatment and intervention of AI in identifying anxiety and depression

Personalization is a much-discussed approach to improving compliance and outcomes for digital mental health interventions (DMHIs). DMHI's unique delivery channel provides new ways to improve the management of those suffering from anxiety and depression. The significance of accommodating patient's preferences for treatment outcomes in mental healthcare has been well established [95]. Therefore, personalizing treatments and interventions to individual needs is a promising approach to improving care for mental health illnesses and beyond [96-98].

The main objective of personalized treatment and intervention applied in mental health is to improve precision in disease diagnosis, treatment choices, responses, and prognosis. Diverse approaches and techniques, namely genomics, epi-genomics, neural circuits, and AI, are related to precision psychiatry. Using computational and biological tools to find potential biomarkers, patients with the same endo-phenotype will likely receive biomarker-based treatment and management, thus leading to a better prognosis [99].

Digital therapeutics (DTx) involves qualified software programs to manage, prevent, and treat medical conditions and is an emerging type of medical therapy. The products and devices that fall under this, such as wearable devices, smartphones, e-therapy, and chatbots, have been developed for a wide range of medical conditions such as diabetes, oncology treatment and management, and neuropsychiatric disorders, including anxiety and depression. One of the main advantages of DTx with AI is that it can be more flexible compared to other treatment methods to address patients' individual needs. DTx is developed for specific medical conditions, based on science and evidence-based clinical medicine, and approved by the FDA [100].

DTx can be used either as monotherapy or in combination with other forms of therapy, like medications, to improve outcomes [101]. With technological advancements, research has explored the use of AI in managing mental disorders with a personalized approach and treatment plan. For instance, technology-based behavioral sensing is promising in measuring subjective functioning, guiding management and treatment, and making inferences concerning symptoms. An example is the self-help tool, downloaded through mobile apps [102].

Research supports the effectiveness of internet-based interventions in the self-management of depression, along with symptom-specific interventions. For example, Deprex's program is relevant to symptomatic improvement in mild to moderate cases [103]. Such findings support the need for increased specificity in designing automated self-help programs [104]. Therefore, the treatment plan can be tailored as per the person's symptoms, preferences, and needs when considering the AI approach rather than conventional medicine. However, it is too early to draw firm conclusions regarding the effectiveness of these treatments based on the evidence of their efficacy [105].

## Behavioural and lifestyle changes for outpatient compliance (wearable devices, digital therapies and follow-up of mood monitoring)

In the past decade or two we have seen an implication of AI in clinical and research medicine, which has led to a shift from the traditional face-face consultation to technology driven interventions or e-therapies. Recent reviews have shown e-therapies to be growing in popularity among people as well as being effective [106]. A potential hurdle seen in evaluating these technologies is user compliance [107]. Not much is known about the degree to which user's engagement aligns with the usage patterns for which these technologies are designed. Also, little is known regarding the influence of technology adherence on outcomes. In medicine literature, compliance- "The extent to which a person's behaviour, that is- Taking medications, following a

diet and/or executing lifestyle changes, corresponds with the agreed recommendations by a health care provider” persistence, and the act of compliance for the advised duration of time, are widely studied [108,109]. These behavioural variables are seen to significantly impact medical and psychotherapy outcomes [110]. In e-therapies the equivalent of failing to persist with therapy is treatment drop out, that is- when a user prematurely discontinues the use of intervention/technology. Appreciation of persistence and adherence is significant in evaluating e-therapy, including an understanding of compliance to the program, such as completion of modules and/ or e/online activities. As the field of e-therapy has been evolving, so has the interest in potentially modifiable factors that may affect compliance [110].

Program usability testing is an important factor. According to recent studies, the increased use of computer relational skills, such as use of social dialogue and empathy in computer programs, eventually leads to an increased usage of these devices and programs [111]. Several authors have started to explore the effect of trial factors and reminders on cessation of usage and thus compliance. Clarke and Colleagues comparison of overcoming depression concluded that people were more likely to demonstrate compliance if they received reminders [112]. For outpatient compliance, engagement in e-therapy and smart devices requires more cognitive, physical and time investment by the person as compared to the relative ease of taking medication daily. This may answer as to why e-therapy users are more prone to non-adherence. Compliance can be measure through objective and subjective methods. Objectives measures include the time spent online, frequency of the program being accessed by the user, number of completed activities and the patterns of usage. While subjective measures include the completion of behaviour-based activities, usage of skills along with the time spent online.

Compliance with e-therapy was also seen to be influenced by their design, application and logistics, the same way medication dosing affects outcomes [113]. Therefore, adherence/compliance is essential in understanding how these therapies may benefit individuals who need intervention. The most common use of e-therapy is to intervene in anxiety and depression.

In a randomized controlled trial (RCT), therapy provided with Eleos Health showed superior anxiety and depression outcomes, compared to TAU. These findings indicated that complementing mental health services with an AI platform specializing in behavioural treatment was more effective in reducing key symptoms compared to standard therapy [113]. With studies and research, we can see that e-therapy and AI embedded technologies such as smartphones and wearable devices have the potential to detect and monitor anxiety and depression, however, are not advanced enough for clinical use. Until further evidence demonstrates an ideal performance of the above, they should be used along with other clinical assessments.

### **Advantages of utilizing AI for diagnosis and treatment of depression and anxiety**

Traditional methods of identifying depression and anxiety are often reliant on self-reporting and clinician assessments. These methods suffer from inherent limitations - stigma, social desirability bias, and underdiagnoses are just a few hurdles hindering timely intervention [10,14]. As the development of larger and deeper AI networks continues development at neck-breaking speed, the potential of AI in diagnosing depression and anxiety, along with other mental health disorders, flickers on the horizon.

AI algorithms, trained on vast datasets of behavioral and linguistic patterns, can theoretically analyze speech, text, and even facial expressions to detect the subtle telltale signs of these widespread mental health concerns [19,20]. Moreover, by identifying subtle behavioral and linguistic changes associated with depression and anxiety, AI algorithms can potentially detect and diagnose these conditions earlier and with greater accuracy, paving the way for improved outcomes. This early detection holds immense promise for preventing symptom escalation, reducing healthcare burdens, and ultimately, transforming the lives of millions struggling with these debilitating conditions. Therefore, the landscape of mental health diagnosis is poised for a transformative shift with the emergence of artificial intelligence [20].

AI algorithms can go over tremendous amounts of data to identify patterns and trends invisible to the human eye, offering clinicians a more holistic understanding of their patients' conditions. This data-driven approach can inform personalized treatment plans, tailoring interventions to individual needs and preferences [114]. Furthermore, AI can also help people with mental health issues who find it challenging to have human interactions, especially with people who are afraid of social stigma, by utilizing AI through virtual therapists, chatbots, or other channels, they can seek help privately and provide convenience to their daily lives [12]. Additionally, AI can provide valuable support in tasks like symptom monitoring and early detection of relapse, allowing clinicians to focus on building therapeutic relationships and delivering high-quality care as AI techniques will redefine mental illnesses more objectively than current practices such as the DSM-5 [10,115].

### **Limitations of using AI for screening and diagnosis of depression and anxiety**

The implementation of AI in the sector of mental health possesses many challenges related to safety and

security of data, autonomy of patients, and effectiveness of its use [66,116,117]. As AI uses different external servers for storing data, there is always a risk of security breach and leaking of personal data [75]. Additionally, accuracy of diagnosing depression and anxiety using AI tools is still questionable for example wearable AI devices are not always accurate and hence the diagnosis made using the data provided by such devices cannot be relied on [75]. This in turn leads to another major concern, that is, there is no clarity of accountability when an AI system makes an error, hence patient won't know who to hold accountable if there is any wrong diagnosis or treatment, even if it leads to detrimental effects on patients' health [118]. Similarly, patients' autonomy is also important to be taken care of, but unfortunately AI tools have failed to prove their transparency [119].

The inherent complexity of mental health, characterized by overlapping symptoms and individual variability, poses a significant challenge for AI algorithms to navigate. It is a well-known fact that psychiatry is a field where doctor-patient relationship, understanding and compassion is crucial for diagnosis and treatment [118]. The drawback of using AI is that it lacks these essential skills, hence, can lead to wrong diagnosis. Likewise, when using AI wearable devices, they can only record physiological data and cannot determine its subjective nature, for instance a smart watch can detect changes in heart rate but cannot determine what has caused that. Correct interpretation of such data is essential, similarly considering the emotions of patients is also very important and a crucial part of treatment, which can currently only be done by a mental health provider and not a robot or computer. Therefore, the use of AI in psychiatry is limited to being a complementary tool which cannot completely replace the role of trained mental health practitioners for diagnosis and treatment of depression and anxiety [120].

Acceptability of AI amongst patients also limits its use, as some cultures still find it disrespectful to be treated by a machine [121]. Another major issue is limited availability of technology in resource-limited areas, and lack of training for using such technologies amongst health care professionals of such areas [122]. Therefore, such technology can only be used in developed areas and hence deprive underprivileged areas of equal share in healthcare facilities. Furthermore, another important concern is that use of AI might make patients overly dependent on technology which can in turn lead to avoidance of face-to-face interactions with health care providers. Moreover, biases embedded within training data can lead to discriminatory outcomes, particularly for the marginalized groups [123]. Most importantly, there is still a lack of legal regulations, standard guidelines, and an unanimously accepted framework for use of AI in medical field [75]. Such guidelines and laws are vitally important for widespread use and acceptability of AI in the field of mental health and to maintain standard protocol of its use.

## Future of artificial intelligence in mental health

The journey from algorithms to applications for AI in identifying depression and anxiety is just beginning. The actual value of AI lies in its translation from theoretical promises to practical applications. Integrating AI tools into clinical settings holds immense promise for improving patient care. Imagine AI-powered screening tools used during routine check-ups, providing initial assessments, and flagging potential cases for further evaluation. Telehealth platforms could leverage AI to offer real-time emotional support and personalized interventions, bridging geographical and accessibility barriers. Additionally, AI could analyse vast amounts of clinical data to identify patterns and inform the development of more targeted and effective treatment plans.

However, bridging the gap between potential and practice requires careful consideration. Responsible and ethical AI implementation in mental health requires meticulous data collection practices, transparent model development, and ongoing validation studies to address these challenges and ensure equitable access to accurate and reliable AI-powered diagnostics [115]. Ensuring the affordability and accessibility of AI-powered tools is paramount to reaching individuals who need them most. Mitigating algorithmic bias and addressing data privacy and security concerns are also essential for building trust and encouraging patient engagement with these innovative technologies [14,124]. Moreover, clinicians must have the knowledge and skills to interpret and integrate AI-generated insights into their clinical practice. By prioritizing ethical considerations, fostering robust partnerships, and developing user-friendly and accessible tools, the bridge between research and clinical practice can be successfully navigated, bringing the benefits of early detection and intervention to a broader population [124].

Integrating AI into existing healthcare systems requires seamless data sharing and collaboration between mental health professionals and tech developers [125]. The current potential of AI in mental health lies not in replacing clinicians but rather in empowering them with valuable insights and tools. Ultimately, the successful integration of AI into clinical practice requires a collaborative approach, where clinicians leverage the power of AI to augment their expertise, which improves patient outcomes and a more efficient healthcare system. Therefore, the future of mental health diagnosis and treatment lies in a collaborative approach where AI and human expertise work in tandem. By fostering collaboration and harnessing the strengths of humans and machines, we can work towards a future where mental health support is accessible.

## Conclusions

From various research studies, we conclude that AI can be used to diagnose disease, develop personalized

treatment plans, and assist clinicians in decision-making. Another benefit linked with AI technology is enhancing patient care across healthcare settings rather than just automating tasks, as one would assume. However, certain drawbacks and challenges are faced with its use, such as the need for human expertise, data privacy, and bias. These should be addressed for the effective and responsible implementation of AI in healthcare.

## Additional Information

### Author Contributions

All authors have reviewed the final version to be published and agreed to be accountable for all aspects of the work.

**Concept and design:** Zahra Nazir, Fabeha Zafar, Laraib Fakhare Alam, Rafael R. Vivas, Jada Wang, Sameer Mehmood, See Jia Whei, Mohit Lakkimsetti, Amirali Sadeghzadegan

**Acquisition, analysis, or interpretation of data:** Zahra Nazir, Fabeha Zafar, Laraib Fakhare Alam, Rafael R. Vivas, Jada Wang, Sameer Mehmood, See Jia Whei, Mohit Lakkimsetti, Amirali Sadeghzadegan

**Drafting of the manuscript:** Zahra Nazir, Fabeha Zafar, Laraib Fakhare Alam, Rafael R. Vivas, Jada Wang, Sameer Mehmood, See Jia Whei, Mohit Lakkimsetti, Amirali Sadeghzadegan

**Critical review of the manuscript for important intellectual content:** Zahra Nazir, Fabeha Zafar, Laraib Fakhare Alam, Rafael R. Vivas, Jada Wang, Sameer Mehmood, See Jia Whei, Mohit Lakkimsetti, Amirali Sadeghzadegan

**Supervision:** Zahra Nazir

### Disclosures

**Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

## References

1. John OP, Gross JJ: Healthy and unhealthy emotion regulation: personality processes, individual differences, and life span development. *J Pers.* 2004, 72:1301-33. [10.1111/j.1467-6494.2004.00298.x](https://doi.org/10.1111/j.1467-6494.2004.00298.x)
2. Goldin PR, McRae K, Ramel W, Gross JJ: The neural bases of emotion regulation: reappraisal and suppression of negative emotion. *Biol Psychiatry.* 2008, 63:577-86. [10.1016/j.biopsych.2007.05.031](https://doi.org/10.1016/j.biopsych.2007.05.031)
3. Hallam GP, Webb TL, Sheeran P, et al.: The neural correlates of emotion regulation by implementation intentions. *PLoS One.* 2015, 10:e0119500. [10.1371/journal.pone.0119500](https://doi.org/10.1371/journal.pone.0119500)
4. Gałecki P, Talarowska M: Cognition, emotions, depression, inflammable processes-basic principles of the neurodevelopmental theory of depression. *Neuropsychologia.* 2017, 12:30-7. [10.5114/nan.2017.68899](https://doi.org/10.5114/nan.2017.68899)
5. Depressive disorder (depression). (2023). Accessed: 03.31.2023: <https://www.who.int/news-room/fact-sheets/detail/depression>.
6. Stringaris A: Editorial: what is depression?. *J Child Psychol Psychiatry.* 2017, 58:1287-9. [10.1111/jcpp.12844](https://doi.org/10.1111/jcpp.12844)
7. Kalin NH: The critical relationship between anxiety and depression. *Am J Psychiatry.* 2020, 177:365-7. [10.1176/appi.ajp.2020.20030305](https://doi.org/10.1176/appi.ajp.2020.20030305)
8. Gorman JM: Comorbid depression and anxiety spectrum disorders. *Depress Anxiety.* 1996, 4:160-8. [10.1002/\(SICI\)1520-6394\(1996\)4:4<160::AID-DA2>3.0.CO;2-J](https://doi.org/10.1002/(SICI)1520-6394(1996)4:4<160::AID-DA2>3.0.CO;2-J)
9. Graham S, Depp C, Lee EE, Nebeker C, Tu X, Kim HC, Jeste DV: Artificial intelligence for mental health and mental illnesses: an overview. *Curr Psychiatry Rep.* 2019, 21:116. [10.1007/s11920-019-1094-0](https://doi.org/10.1007/s11920-019-1094-0)
10. Opoku Asare K, Terhorst Y, Vega J, Peltonen E, Lagerspetz E, Ferreira D: Predicting depression from smartphone behavioral markers using machine learning methods, hyperparameter optimization, and feature importance analysis: exploratory study. *JMIR Mhealth Uhealth.* 2021, 9:e26540. [10.2196/26540](https://doi.org/10.2196/26540)
11. D'Alfonso S: AI in mental health. *Curr Opin Psychol.* 2020, 36:112-7. [10.1016/j.copsyc.2020.04.005](https://doi.org/10.1016/j.copsyc.2020.04.005)
12. Abd-Alrazaq A, AlSaad R, Aziz S, et al.: Wearable artificial intelligence for anxiety and depression: scoping review. *J Med Internet Res.* 2023, 25:e42672. [10.2196/42672](https://doi.org/10.2196/42672)
13. Abd-Alrazaq A, Alhuwail D, Schneider J, et al.: The performance of artificial intelligence-driven technologies in diagnosing mental disorders: an umbrella review. *NPJ Digit Med.* 2022, 5:87. [10.1038/s41746-022-00651-8](https://doi.org/10.1038/s41746-022-00651-8)
14. Monteith S, Glenn T, Geddes J, Whybrow PC, Achtyes E, Bauer M: Expectations for artificial intelligence (AI) in psychiatry. *Curr Psychiatry Rep.* 2022, 24:709-21. [10.1007/s11920-022-01378-5](https://doi.org/10.1007/s11920-022-01378-5)
15. Lee EE, Torous J, De Choudhury M, et al.: Artificial intelligence for mental health care: clinical applications, barriers, facilitators, and artificial wisdom. *Biol Psychiatry Cogn Neurosci Neuroimaging.* 2021, 6:856-64. [10.1016/j.bpsc.2021.02.001](https://doi.org/10.1016/j.bpsc.2021.02.001)
16. Abd-Alrazaq AA, Rababeh A, Alajlani M, Bewick BM, Househ M: Effectiveness and safety of using chatbots to improve mental health: systematic review and meta-analysis. *J Med Internet Res.* 2020, 22:e16021.

- [10.2196/16021](#)
17. Adelman CB, Panza KE, Bartley CA, Bontempo A, Bloch MH: A meta-analysis of computerized cognitive-behavioral therapy for the treatment of DSM-5 anxiety disorders. *J Clin Psychiatry*. 2014, 75:e695-704. [10.4088/JCP.13r08894](#)
  18. Wang K, Varma DS, Prosperi M: A systematic review of the effectiveness of mobile apps for monitoring and management of mental health symptoms or disorders. *J Psychiatr Res*. 2018, 107:73-8. [10.1016/j.jpsychires.2018.10.006](#)
  19. Vatansever S, Schlessinger A, Wacker D, Kaniskan HÜ, Jin J, Zhou MM, Zhang B: Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: state-of-the-arts and future directions. *Med Res Rev*. 2021, 41:1427-73. [10.1002/med.21764](#)
  20. Manju LJ, Kanoongo N: Depression detection using emotional artificial intelligence and machine learning: a closer review. *Mater Today Proc*. 2022, 58:217-26. [10.1016/j.matpr.2022.01.467](#)
  21. Mehta A, Niles AN, Vargas JH, Marafon T, Couto DD, Gross JJ: Acceptability and effectiveness of artificial intelligence therapy for anxiety and depression (Youper): longitudinal observational study. *J Med Internet Res*. 2021, 23:e26771. [10.2196/26771](#)
  22. Santoni de Sio F, Mecacci G: Four responsibility gaps with artificial intelligence: why they matter and how to address them. *Philos Technol*. 2021, 34:1057-84. [10.1007/s13347-021-00450-x](#)
  23. Villarreal-Zegarra D, Barrera-Begazo J, Otazú-Alfaro S, Mayo-Puchoc N, Bazo-Alvarez JC, Huarcaya-Victoria J: Sensitivity and specificity of the Patient Health Questionnaire (PHQ-9, PHQ-8, PHQ-2) and General Anxiety Disorder scale (GAD-7, GAD-2) for depression and anxiety diagnosis: a cross-sectional study in a Peruvian hospital population. *BMJ Open*. 2023, 13:e076193. [10.1136/bmjopen-2023-076193](#)
  24. Raue PJ, Brown EL, Bruce ML: Assessing behavioral health using OASIS: Part 1: depression and suicidality. *Home Healthc Nurse*. 2002, 20:154-61. [10.1097/00004045-200203000-00006](#)
  25. Vieira ER, Brown E, Raue P: Depression in older adults: screening and referral. *J Geriatr Phys Ther*. 2014, 37:24-30. [10.1519/JPT.0b013e31828df26f](#)
  26. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. American Psychiatric Association, Washington, DC; 2013. [10.1176/appi.books.9780890425596](#)
  27. Costantini L, Pasquarella C, Odone A, et al.: Screening for depression in primary care with Patient Health Questionnaire-9 (PHQ-9): a systematic review. *J Affect Disord*. 2021, 279:473-83. [10.1016/j.jad.2020.09.131](#)
  28. Spitzer RL, Kroenke K, Williams JB: Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. *JAMA*. 1999, 282:1737-44. [10.1001/jama.282.18.1737](#)
  29. Kroenke K, Spitzer RL, Williams JB: The Patient Health Questionnaire-2: validity of a two-item depression screener. *Med Care*. 2003, 41:1284-92. [10.1097/01.MLR.0000093487.78664.3C](#)
  30. Plummer F, Manea L, Trepel D, McMillan D: Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. *Gen Hosp Psychiatry*. 2016, 39:24-31. [10.1016/j.genhosppsych.2015.11.005](#)
  31. DeGeorge KC, Grover M, Streeter GS: Generalized anxiety disorder and panic disorder in adults. *Am Fam Physician*. 2022, 106:157-64.
  32. Ukwuoma CC, Qin Z, Belal Bin Heyat M, et al.: A hybrid explainable ensemble transformer encoder for pneumonia identification from chest X-ray images. *J Adv Res*. 2023, 48:191-211. [10.1016/j.jare.2022.08.021](#)
  33. Kim JW, Jones KL, D'Angelo E: How to prepare prospective psychiatrists in the era of artificial intelligence. *Acad Psychiatry*. 2019, 43:537-9. [10.1007/s40596-019-01025-x](#)
  34. Fitzpatrick KK, Darcy A, Vierhile M: Delivering cognitive behavior therapy to young adults with symptoms of depression and anxiety using a fully automated conversational agent (woebot): a randomized controlled trial. *JMIR Ment Health*. 2017, 4:e19. [10.2196/mental.7785](#)
  35. Williams AD, Andrews G: The effectiveness of Internet cognitive behavioural therapy (iCBT) for depression in primary care: a quality assurance study. *PLoS One*. 2013, 8:e57447. [10.1371/journal.pone.0057447](#)
  36. Nichols L, Ryan R, Connor C, Birchwood M, Marshall T: Derivation of a prediction model for a diagnosis of depression in young adults: a matched case-control study using electronic primary care records. *Early Interv Psychiatry*. 2018, 12:444-55. [10.1111/eip.12332](#)
  37. Chowdhury M, Cervantes EG, Chan WY, Seitz DP: Use of machine learning and artificial intelligence methods in geriatric mental health research involving electronic health record or administrative claims data: a systematic review. *Front Psychiatry*. 2021, 12:738466. [10.3389/fpsy.2021.738466](#)
  38. Bi Q, Goodman KE, Kaminsky J, Lessler J: What is machine learning? A primer for the epidemiologist. *Am J Epidemiol*. 2019, 188:2222-39. [10.1093/aje/kwz189](#)
  39. Thesmar D, Sraer D, Pinheiro L, Dadson N, Veliche R, Greenberg P: Combining the power of artificial intelligence with the richness of healthcare claims data: opportunities and challenges. *Pharmacoeconomics*. 2019, 37:745-52. [10.1007/s40273-019-00777-6](#)
  40. Wiemken TL, Kelley RR: Machine learning in epidemiology and health outcomes research. *Annu Rev Public Health*. 2020, 41:21-36. [10.1146/annurev-publhealth-040119-094437](#)
  41. Luo W, Phung D, Tran T, et al.: Guidelines for developing and reporting machine learning predictive models in biomedical research: a multidisciplinary view. *J Med Internet Res*. 2016, 18:e523. [10.2196/jmir.5870](#)
  42. Latif J, Xiao C, Tu S, Rehman S, Imran A, Bilal A: Implementation and use of disease diagnosis systems for electronic medical records based on machine learning: a complete review. *IEEE Access*. 2020, 8:150489-513. [10.1109/ACCESS.2020.3016782](#)
  43. Matheny ME, Whicher D, Thadaney Israni S: Artificial intelligence in health care: a report from the National Academy of Medicine. *JAMA*. 2020, 323:509-10. [10.1001/jama.2019.21579](#)
  44. Thieme A, Belgrave D, Doherty G: Machine learning in mental health: a systematic review of the HCI literature to support the development of effective and implementable ML systems. *ACM Trans Comput Hum Int*. 2020, 27:1-53. [10.1145/3398069](#)
  45. Shatte AB, Hutchinson DM, Teague SJ: Machine learning in mental health: a scoping review of methods and applications. *Psychol Med*. 2019, 49:1426-48. [10.1017/S0033291719000151](#)
  46. Rahman R, Al-Garadi MA: Application of machine learning methods in mental health detection: a systematic review. *IEEE Access*. 2020, 8:183952-64.

47. Iyortsuun NK, Kim SH, Jhon M, Yang HJ, Pant S: A review of machine learning and deep learning approaches on mental health diagnosis. *Healthcare (Basel)*. 2023, 11:[10.3390/healthcare11030285](https://doi.org/10.3390/healthcare11030285)
48. Tsugawa S, Kikuchi Y, Kishino F, Nakajima K, Itoh Y, Ohsaki H: Recognizing depression from Twitter activity. *ACM Conf Hum Factors Comput Syst*. 2015,
49. Kandias M, Gritzalis D, Stavrou V, Nikoloulis K: Stress level detection via OSN usage pattern and chronicity analysis: an OSINT threat intelligence module. *Comput Secur*. 2017, 69:3-17. [10.1016/j.cose.2016.12.003](https://doi.org/10.1016/j.cose.2016.12.003)
50. Deshpande M, Rao V: Depression detection using emotion artificial intelligence. *Conf Intell Sustain Syst*. 2017, 858-62. [10.1109/ISSI.2017.8389299](https://doi.org/10.1109/ISSI.2017.8389299)
51. Noorbakhsh-Sabet N, Zand R, Zhang Y, Abedi V: Artificial intelligence transforms the future of health care. *Am J Med*. 2019, 132:795-801. [10.1016/j.amjmed.2019.01.017](https://doi.org/10.1016/j.amjmed.2019.01.017)
52. Le Glaz A, Haralambous Y, Kim-Dufor DH, et al.: Machine learning and natural language processing in mental health: systematic review. *J Med Internet Res*. 2021, 23:e15708. [10.2196/15708](https://doi.org/10.2196/15708)
53. Malgaroli M, Hull TD, Zech JM, Althoff T: Natural language processing for mental health interventions: a systematic review and research framework. *Transl Psychiatry*. 2023, 13:309. [10.1038/s41398-023-02592-2](https://doi.org/10.1038/s41398-023-02592-2)
54. Chen ZS, Kulkarni PP, Galatzer-Levy IR, Bigio B, Nasca C, Zhang Y: Modern views of machine learning for precision psychiatry. *Patterns (N Y)*. 2022, 3:100602. [10.1016/j.patter.2022.100602](https://doi.org/10.1016/j.patter.2022.100602)
55. Liu Z, Peach RL, Lawrance EL, Noble A, Ungless MA, Barahona M: Listening to mental health crisis needs at scale: using natural language processing to understand and evaluate a mental health crisis text messaging service. *Front Digit Health*. 2021, 3:779091. [10.3389/fdgth.2021.779091](https://doi.org/10.3389/fdgth.2021.779091)
56. Chi NT: Mental healthcare chatbot based on natural language processing and deep learning approaches: Ted the therapist. *Int J Inf Technol*. 2022, 14:3757-66. [10.1007/s41870-022-00999-6](https://doi.org/10.1007/s41870-022-00999-6)
57. Minerva F, Giubilini A: Is AI the future of mental healthcare?. *Topoi (Dordr)*. 2023, 42:1-9. [10.1007/s11245-023-09932-3](https://doi.org/10.1007/s11245-023-09932-3)
58. Zhang T, Schoene AM, Ji S, Ananiadou S: Natural language processing applied to mental illness detection: a narrative review. *NPJ Digit Med*. 2022, 5:46. [10.1038/s41746-022-00589-7](https://doi.org/10.1038/s41746-022-00589-7)
59. Straw I, Callison-Burch C: Artificial intelligence in mental health and the biases of language based models. *PLoS One*. 2020, 15:e0240376. [10.1371/journal.pone.0240376](https://doi.org/10.1371/journal.pone.0240376)
60. Abd-Alrazaq AA, Alajlani M, Alalwan AA, Bewick BM, Gardner P, Househ M: An overview of the features of chatbots in mental health: a scoping review. *Int J Med Inform*. 2019, 132:103978. [10.1016/j.ijmedinf.2019.103978](https://doi.org/10.1016/j.ijmedinf.2019.103978)
61. Fiske A, Henningsen P, Buyx A: Your robot therapist will see you now: ethical implications of embodied artificial intelligence in psychiatry, psychology, and psychotherapy. *J Med Internet Res*. 2019, 21:e13216. [10.2196/13216](https://doi.org/10.2196/13216)
62. Sharma B, Puri H, Rawat D: Digital psychiatry-curbing depression using therapy chatbot and depression analysis. *IEEE*. 2018, 627-31. [10.1109/ICICCT.2018.8472986](https://doi.org/10.1109/ICICCT.2018.8472986)
63. Madhu D, Jain C, Sebastain E, et al.: A novel approach for medical assistance using trained chatbot. *ICICCT*. 2017, 243-6. [10.1109/ICICCT.2017.7975195](https://doi.org/10.1109/ICICCT.2017.7975195)
64. Ayers JW, Poliak A, Dredze M, et al.: Comparing physician and artificial intelligence chatbot responses to patient questions posted to a public social media forum. *JAMA Intern Med*. 2023, 183:589-96. [10.1001/jamainternmed.2023.1838](https://doi.org/10.1001/jamainternmed.2023.1838)
65. Denecke K, Abd-Alrazaq A, Househ M: Artificial intelligence for chatbots in mental health: opportunities and challenges. *Multiple Perspective Artificial Intelligence Healthcare*. 2021. [10.1007/978-3-030-67503-1\\_10](https://doi.org/10.1007/978-3-030-67503-1_10)
66. Doraiswamy S, Abraham A, Mamtani R, Cheema S: Use of telehealth during the COVID-19 pandemic: scoping review. *J Med Internet Res*. 2020, 22:e24087. [10.2196/24087](https://doi.org/10.2196/24087)
67. Pham KT, Nabizadeh A, Selekt S: Artificial intelligence and chatbots in psychiatry. *Psychiatr Q*. 2022, 93:249-53. [10.1007/s11126-022-09973-8](https://doi.org/10.1007/s11126-022-09973-8)
68. Garety P, Edwards CJ, Ward T, et al.: Optimising AVATAR therapy for people who hear distressing voices: study protocol for the AVATAR2 multi-centre randomised controlled trial. *Trials*. 2021, 22:366. [10.1186/s13063-021-05301-w](https://doi.org/10.1186/s13063-021-05301-w)
69. Welch V, Wy TJ, Ligezka A, Hassett LC, Croarkin PE, Athreya AP, Romanowicz M: Use of mobile and wearable artificial intelligence in child and adolescent psychiatry: scoping review. *J Med Internet Res*. 2022, 24:e35560. [10.2196/35560](https://doi.org/10.2196/35560)
70. Elgendi M, Menon C: Assessing anxiety disorders using wearable devices: challenges and future directions. *Brain Sci*. 2019, 9:[10.3390/brainsci9030050](https://doi.org/10.3390/brainsci9030050)
71. Sequeira L, Perrotta S, LaGrassa J, et al.: Mobile and wearable technology for monitoring depressive symptoms in children and adolescents: a scoping review. *J Affect Disord*. 2020, 265:314-24. [10.1016/j.jad.2019.11.156](https://doi.org/10.1016/j.jad.2019.11.156)
72. Murray CJ, Vos T, Lozano R, et al.: Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*. 2012, 380:2197-225. [10.1016/S0140-6736\(12\)61689-4](https://doi.org/10.1016/S0140-6736(12)61689-4)
73. Oladeji BD, Gureje O: Brain drain: a challenge to global mental health. *BJPsych Int*. 2016, 13:61-3. [10.1192/s2056474000001240](https://doi.org/10.1192/s2056474000001240)
74. Lee S, Kim H, Park MJ, Jeon HJ: Current advances in wearable devices and their sensors in patients with depression. *Front Psychiatry*. 2021, 12:672347. [10.3389/fpsy.2021.672347](https://doi.org/10.3389/fpsy.2021.672347)
75. Kang M, Chai K: Wearable sensing systems for monitoring mental health. *Sensors (Basel)*. 2022, 22:[10.3390/s22030994](https://doi.org/10.3390/s22030994)
76. Hunkin H, King DL, Zajac IT: Perceived acceptability of wearable devices for the treatment of mental health problems. *J Clin Psychol*. 2020, 76:987-1003. [10.1002/jclp.22934](https://doi.org/10.1002/jclp.22934)
77. Byeon H: Relationship between physical activity level and depression of elderly people living alone. *Int J Environ Res Public Health*. 2019, 16:[10.3390/ijerph16204051](https://doi.org/10.3390/ijerph16204051)
78. Puccinelli PJ, da Costa TS, Seffrin A, et al.: Correction to: Reduced level of physical activity during COVID-19 pandemic is associated with depression and anxiety levels: an internet-based survey. *BMC Public Health*. 2021, 21:613. [10.1186/s12889-021-10684-1](https://doi.org/10.1186/s12889-021-10684-1)
79. De Mello MT, Lemos Vde A, Antunes HK, Bittencourt L, Santos-Silva R, Tufik S: Relationship between

- physical activity and depression and anxiety symptoms: a population study. *J Affect Disord.* 2013, 149:241-6. [10.1016/j.jad.2013.01.035](https://doi.org/10.1016/j.jad.2013.01.035)
80. Raoux N, Benoit O, Dantchev N, et al.: Circadian pattern of motor activity in major depressed patients undergoing antidepressant therapy: relationship between actigraphic measures and clinical course. *Psychiatry Res.* 1994, 52:85-98. [10.1016/0165-1781\(94\)90122-8](https://doi.org/10.1016/0165-1781(94)90122-8)
  81. Vallance JK, Winkler EA, Gardiner PA, Healy GN, Lynch BM, Owen N: Associations of objectively-assessed physical activity and sedentary time with depression: NHANES (2005-2006). *Prev Med.* 2011, 53:284-8. [10.1016/j.ypmed.2011.07.013](https://doi.org/10.1016/j.ypmed.2011.07.013)
  82. Lovato N, Gradisar M: A meta-analysis and model of the relationship between sleep and depression in adolescents: recommendations for future research and clinical practice. *Sleep Med Rev.* 2014, 18:521-9. [10.1016/j.smrv.2014.03.006](https://doi.org/10.1016/j.smrv.2014.03.006)
  83. Ramsawh HJ, Stein MB, Belik SL, Jacobi F, Sareen J: Relationship of anxiety disorders, sleep quality, and functional impairment in a community sample. *J Psychiatr Res.* 2009, 43:926-33. [10.1016/j.jpsychires.2009.01.009](https://doi.org/10.1016/j.jpsychires.2009.01.009)
  84. Kemp AH, Quintana DS, Gray MA, Felmingham KL, Brown K, Gatt JM: Impact of depression and antidepressant treatment on heart rate variability: a review and meta-analysis. *Biol Psychiatry.* 2010, 67:1067-74. [10.1016/j.biopsych.2009.12.012](https://doi.org/10.1016/j.biopsych.2009.12.012)
  85. Carney RM, Freedland KE: Depression and heart rate variability in patients with coronary heart disease. *Cleve Clin J Med.* 2009, 76 Suppl 2:S13-7. [10.3949/ccjm.76.s2.03](https://doi.org/10.3949/ccjm.76.s2.03)
  86. Chalmers JA, Quintana DS, Abbott MJ, Kemp AH: Anxiety disorders are associated with reduced heart rate variability: a meta-analysis. *Front Psychiatry.* 2014, 5:80. [10.3389/fpsy.2014.00080](https://doi.org/10.3389/fpsy.2014.00080)
  87. Tazawa Y, Liang KC, Yoshimura M, et al.: Evaluating depression with multimodal wristband-type wearable device: screening and assessing patient severity utilizing machine-learning. *Heliyon.* 2020, 6:e03274. [10.1016/j.heliyon.2020.e03274](https://doi.org/10.1016/j.heliyon.2020.e03274)
  88. Rausch JL, Johnson ME, Corley KM, et al.: Depressed patients have higher body temperature: 5-HT transporter long promoter region effects. *Neuropsychobiology.* 2003, 47:120-7. [10.1159/000070579](https://doi.org/10.1159/000070579)
  89. Burns MN, Begale M, Duffecy J, Gergle D, Karr CJ, Giangrande E, Mohr DC: Harnessing context sensing to develop a mobile intervention for depression. *J Med Internet Res.* 2011, 13:e55. [10.2196/jmir.1858](https://doi.org/10.2196/jmir.1858)
  90. Hariman K, Ventriglio A, Bhugra D: The future of digital psychiatry. *Curr Psychiatry Rep.* 2019, 21:88. [10.1007/s11920-019-1074-4](https://doi.org/10.1007/s11920-019-1074-4)
  91. Kawano M, Sawada K, Shimodera S, et al.: Hippocampal subfield volumes in first episode and chronic schizophrenia. *PLoS One.* 2015, 10:e0117785. [10.1371/journal.pone.0117785](https://doi.org/10.1371/journal.pone.0117785)
  92. Prater KE, Hosanagar A, Klumpp H, Angstadt M, Phan KL: Aberrant amygdala-frontal cortex connectivity during perception of fearful faces and at rest in generalized social anxiety disorder. *Depress Anxiety.* 2013, 30:234-41. [10.1002/da.22014](https://doi.org/10.1002/da.22014)
  93. Yadav SK, Gothe MP, Haslem LA, et al.: Machine learning to classify bipolar and unipolar depression using fMRI data: a systematic review and multivariate pattern analysis. *NeuroImage.* 2023, 13:2523. [10.3390/diagnostics13142523](https://doi.org/10.3390/diagnostics13142523)
  94. Swift JK, Callahan JL, Cooper M, Parkin SR: The impact of accommodating client preference in psychotherapy: a meta-analysis. *J Clin Psychol.* 2018, 74:1924-37. [10.1002/clp.22680](https://doi.org/10.1002/clp.22680)
  95. Aung MH, Matthews M, Choudhury T: Sensing behavioral symptoms of mental health and delivering personalized interventions using mobile technologies. *Depress Anxiety.* 2017, 34:603-9. [10.1002/da.22646](https://doi.org/10.1002/da.22646)
  96. Chawla NV, Davis DA: Bringing big data to personalized healthcare: a patient-centered framework. *J Gen Intern Med.* 2013, 28 Suppl 3:S660-5. [10.1007/s11606-013-2455-8](https://doi.org/10.1007/s11606-013-2455-8)
  97. Andrews G, Williams AD: Internet psychotherapy and the future of personalized treatment. *Depress Anxiety.* 2014, 31:912-5. [10.1002/da.22302](https://doi.org/10.1002/da.22302)
  98. Chen J, Hu S: Individualized treatment strategy for depressive disorder. *Adv Exp Med Biol.* 2019, 1180:219-32. [10.1007/978-981-32-9271-0\\_12](https://doi.org/10.1007/978-981-32-9271-0_12)
  99. Hong JS, Wasden C, Han DH: Introduction of digital therapeutics. *Comput Methods Programs Biomed.* 2021, 209:106319. [10.1016/j.cmpb.2021.106319](https://doi.org/10.1016/j.cmpb.2021.106319)
  100. Robson K, Plangger K, Kietzmann J, et al.: Is it all a game? Understanding the principles of gamification. *ISSN.* 2015, 58:411-20. [10.1016/j.bushor.2015.03.006](https://doi.org/10.1016/j.bushor.2015.03.006)
  101. Ben-Zeev D, Davis KE, Kaiser S, Krzoss I, Drake RE: Mobile technologies among people with serious mental illness: opportunities for future services. *Adm Policy Ment Health.* 2013, 40:340-3. [10.1007/s10488-012-0424-x](https://doi.org/10.1007/s10488-012-0424-x)
  102. Twomey C, O'Reilly G, Meyer B: Effectiveness of an individually-tailored computerised CBT programme (Deprexis) for depression: a meta-analysis. *Psychiatry Res.* 2017, 256:371-7. [10.1016/j.psychres.2017.06.081](https://doi.org/10.1016/j.psychres.2017.06.081)
  103. Boschloo L, Cuijpers P, Karyotaki E, Berger T, Moritz S, Meyer B, Klein JP: Symptom-specific effectiveness of an internet-based intervention in the treatment of mild to moderate depressive symptomatology: the potential of network estimation techniques. *Behav Res Ther.* 2019, 122:103440. [10.1016/j.brat.2019.103440](https://doi.org/10.1016/j.brat.2019.103440)
  104. Kenter RM, Cuijpers P, Beekman A, van Straten A: Effectiveness of a web-based guided self-help intervention for outpatients with a depressive disorder: short-term results from a randomized controlled trial. *J Med Internet Res.* 2016, 18:e80. [10.2196/jmir.4861](https://doi.org/10.2196/jmir.4861)
  105. Barak A, Herbst LH, Nissim MB, et al.: A comprehensive review and a meta-analysis of the effectiveness of Internet-based psychotherapeutic interventions. *J Technol Hum Serv.* 2008, 26:109-60. [10.1080/15228830802094429](https://doi.org/10.1080/15228830802094429)
  106. Eysenbach G: Issues in evaluating health websites in an Internet-based randomized controlled trial. *J Med Internet Res.* 2002, 4:E17. [10.2196/jmir.4.3.e17](https://doi.org/10.2196/jmir.4.3.e17)
  107. Chaudri NA: Adherence to long-term therapies evidence for action. *Ann Saudi Med.* 2004, 24:221-2. [10.5144/0256-4947.2004.221](https://doi.org/10.5144/0256-4947.2004.221)
  108. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK: Medication compliance and persistence: terminology and definitions. *Value Health.* 2008, 11:44-7. [10.1111/j.1524-4753.2007.00213.x](https://doi.org/10.1111/j.1524-4753.2007.00213.x)
  109. Coon DW, Thompson LW: The relationship between homework compliance and treatment outcomes among older adult outpatients with mild-to-moderate depression. *Am J Geriatr Psychiatry.* 2003, 11:53-61.

110. Bickmore T, Gruber A, Picard R: Establishing the computer-patient working alliance in automated health behavior change interventions. *Patient Educ Couns*. 2005, 59:21-30. [10.1016/j.pec.2004.09.008](https://doi.org/10.1016/j.pec.2004.09.008)
111. Clarke G, Eubanks D, Reid E, et al.: Overcoming Depression on the Internet (ODIN) (2): a randomized trial of a self-help depression skills program with reminders. *J Med Internet Res*. 2005, 7:e16. [10.2196/jmir.7.2.e16](https://doi.org/10.2196/jmir.7.2.e16)
112. Donkin L, Christensen H, Naismith SL, Neal B, Hickie IB, Glozier N: A systematic review of the impact of adherence on the effectiveness of e-therapies. *J Med Internet Res*. 2011, 13:e52. [10.2196/jmir.1772](https://doi.org/10.2196/jmir.1772)
113. Češková E, Šilhán P: From personalized medicine to precision psychiatry?. *Neuropsychiatr Dis Treat*. 2021, 17:3663-8. [10.2147/NDT.S337814](https://doi.org/10.2147/NDT.S337814)
114. World Mental Health Report 2022: Transforming Mental Health for All . World Health Organization, Geneva; 2022.
115. Murphy K, Di Ruggiero E, Upshur R, et al.: Artificial intelligence for good health: a scoping review of the ethics literature. *BMC Med Ethics*. 2021, 22:14. [10.1186/s12910-021-00577-8](https://doi.org/10.1186/s12910-021-00577-8)
116. Chiruvella V, Guddati AK: Ethical issues in patient data ownership. *Interact J Med Res*. 2021, 10:e22269. [10.2196/22269](https://doi.org/10.2196/22269)
117. Terra M, Baklola M, Ali S, et al.: Opportunities, applications, challenges and ethical implications of artificial intelligence in psychiatry: a narrative review. *Egypt J Neurol Psychiatry Neurosurg*. 2023, 80:1-10.
118. Char DS, Abràmoff MD, Feudtner C: Identifying ethical considerations for machine learning healthcare applications. *Am J Bioeth*. 2020, 20:7-17. [10.1080/15265161.2020.1819469](https://doi.org/10.1080/15265161.2020.1819469)
119. Brown C, Story GW, Mourão-Miranda J, Baker JT: Will artificial intelligence eventually replace psychiatrists?. *Br J Psychiatry*. 2021, 218:131-4. [10.1192/bjp.2019.245](https://doi.org/10.1192/bjp.2019.245)
120. Kretzschmar K, Tyroll H, Pavarini G, Manzini A, Singh I: Can your phone be your therapist? Young people's ethical perspectives on the use of fully automated conversational agents (Chatbots) in mental health support. *Biomed Inform Insights*. 2019, 11:1178222619829083. [10.1177/1178222619829083](https://doi.org/10.1177/1178222619829083)
121. Sharma S, Rawal R, Shah D: Addressing the challenges of AI-based telemedicine: best practices and lessons learned. *J Educ Health Promot*. 2023, 12:338. [10.4103/jehp.jehp\\_402\\_23](https://doi.org/10.4103/jehp.jehp_402_23)
122. Vaidyam AN, Wisniewski H, Halamka JD, Kashavan MS, Torous JB: Chatbots and conversational agents in mental health: a review of the psychiatric landscape. *Can J Psychiatry*. 2019, 64:456-64. [10.1177/0706743719828977](https://doi.org/10.1177/0706743719828977)
123. Kruse CS, Betancourt JA, Gonzales M, Dickerson K, Neer M: Leveraging mobile health to manage mental health/behavioral health disorders: systematic literature review. *JMIR Ment Health*. 2022, 9:e42301. [10.2196/42301](https://doi.org/10.2196/42301)
124. Eisner E, Berry N, Bucci S: Digital tools to support mental health: a survey study in psychosis . *BMC Psychiatry*. 2023, 23:726. [10.1186/s12888-023-05114-y](https://doi.org/10.1186/s12888-023-05114-y)
125. Battista P, Salvatore C, Berlinger M, Cerasa A, Castiglioni I: Artificial intelligence and neuropsychological measures: the case of Alzheimer's disease. *Neurosci Biobehav Rev*. 2020, 114:211-28. [10.1016/j.neubiorev.2020.04.026](https://doi.org/10.1016/j.neubiorev.2020.04.026)